An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
- Status
- COMPLETED
- Phase
- PHASE1
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Pomalidomide for Kaposi Sarcoma in People With or Without HIV
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- Status
- COMPLETED
- Phase
- PHASE1
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
- Status
- COMPLETED
- Phase
- PHASE3
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE1
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
- Status
- COMPLETED
- Phase
- PHASE3
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2